McKesson Corporation (MCK)
| Market Cap | 122.48B +16.6% |
| Revenue (ttm) | 418.79B +8.2% |
| Net Income | 4.70B +16.5% |
| EPS | 38.98 +21.3% |
| Shares Out | 115.46M |
| PE Ratio | 27.22 |
| Forward PE | 21.66 |
| Dividend | $3.76 (0.35%) |
| Ex-Dividend Date | Dec 1, 2026 |
| Volume | 812,151 |
| Open | 1,051.67 |
| Previous Close | 1,072.00 |
| Day's Range | 1,046.70 - 1,070.15 |
| 52-Week Range | 723.68 - 1,121.50 |
| Beta | 0.28 |
| Analysts | Buy |
| Price Target | 1,129.07 (+6.43%) |
| Earnings Date | Nov 4, 2026 |
About MCK
McKesson Corporation provides healthcare services in the United States and internationally. It operates through four segments: North American Pharmaceutical, Oncology & Multispecialty, Prescription Technology Solutions, and Medical-Surgical Solutions. The company distributes branded, generic, specialty, biosimilar and over-the-counter pharmaceutical drugs, and other healthcare-related products; delivers products to retail pharmacies, hospitals, long-term care centers, clinics, and institutions; and provides logistics and distribution services f... [Read more]
Financial Performance
In fiscal year 2026, McKesson's revenue was $403.43 billion, an increase of 12.36% compared to the previous year's $359.05 billion. Earnings were $4.76 billion, an increase of 44.52%.
Financial StatementsAnalyst Summary
According to 16 analysts, the average rating for MCK stock is "Buy." The 12-month stock price target is $1,129.07, which is an increase of 6.43% from the latest price.
News
McKesson price target raised to $1,260 from $1,207 at Morgan Stanley
Morgan Stanley raised the firm’s price target on McKesson (MCK) to $1,260 from $1,207 and keeps an Overweight rating on the shares.
McKesson price target raised to $1,050 from $1,020 at Mizuho
Mizuho raised the firm’s price target on McKesson (MCK) to $1,050 from $1,020 and keeps a Neutral rating on the shares.
McKesson price target raised to $1,250 from $1,050 at BofA
BofA raised the firm’s price target on McKesson (MCK) to $1,250 from $1,050 and keeps a Buy rating on the shares after the company reported a fiscal Q2 EPS beat.
McKesson price target raised to $965 from $845 at RBC Capital
RBC Capital raised the firm’s price target on McKesson (MCK) to $965 from $845 and keeps a Sector Perform rating on the shares. The company reported a broad based beat…
McKesson price target raised to $1,200 from $1,006 at TD Cowen
TD Cowen raised the firm’s price target on McKesson (MCK) to $1,200 from $1,006 and keeps a Buy rating on the shares. The firm said their results were driven by…
McKesson price target raised to $1,250 from $1,200 at UBS
UBS raised the firm’s price target on McKesson (MCK) to $1,250 from $1,200 and keeps a Buy rating on the shares.
McKesson price target raised to $1,200 from $1,000 at Evercore ISI
Evercore ISI analyst Elizabeth Anderson raised the firm’s price target on McKesson (MCK) to $1,200 from $1,000 and keeps an Outperform rating on the shares.
McKesson price target raised to $1,225 from $1,017 at Baird
Baird raised the firm’s price target on McKesson (MCK) to $1,225 from $1,017 and keeps an Outperform rating on the shares. The firm updated its model following quarterly results. Published…
McKesson reports Q2 adjusted EPS $11.68, consensus $10.75
Reports Q2 revenue $111B, consensus $109.95B. “McKesson (MCK) delivered another quarter of strong results, reflecting operational strength in our core business segments and disciplined execution acros...
McKesson raises FY27 EPS view to $45.60-$46.40 from $44.20-$45
Consensus $44.66.
McKesson Earnings Call Transcript: Q2 2027
Q2 revenue rose 8% and adjusted EPS grew 18% to $11.68, prompting higher FY27 guidance. Growth spanned all segments, alongside strategic expansion through PMG and a planned Option Care investment.
McKesson Earnings release: Q2 2027
McKesson released its Q2 2027 earnings on November 4, 2026, summarizing the period's financial results.
McKesson Slides: Q2 2027
McKesson has posted slides in relation to its Q2 2027 quarterly earnings report, which was published on November 4, 2026.
McKesson Quarterly report: Q2 2027
McKesson has published its Q2 2027 quarterly earnings report on November 4, 2026.
McKesson Reports Fiscal 2027 Second Quarter Results and Raises Full Year Adjusted EPS Guidance
IRVING, Texas--(BUSINESS WIRE)--McKesson Corporation (NYSE: MCK) has released its fiscal 2027 second quarter financial results. Results can be accessed on McKesson's Investor Relations website at inve...
McKesson price target raised to $1,207 from $977 at Morgan Stanley
Morgan Stanley analyst Erin Wright raised the firm’s price target on McKesson (MCK) to $1,207 from $977 and keeps an Overweight rating on the shares.
Cardinal Health, McKesson awarded $2.7B and $741.5M DLA contracts respectively
Cardinal Health (CAH) and McKesson (MCK) have each been awarded fixed-price, indefinite-delivery/indefinite-quantity contracts worth $2.7B and $741.5M respectively under a solicitation for the Medical...
McKesson Corporation Declares Quarterly Dividend
IRVING, Texas--(BUSINESS WIRE)--The Board of Directors of McKesson Corporation (NYSE:MCK) yesterday declared a regular dividend of 94 cents per share of common stock. The dividend will be payable on J...
McKesson price target raised to $1,020 from $905 at Mizuho
Mizuho raised the firm’s price target on McKesson (MCK) to $1,020 from $905 and keeps a Neutral rating on the shares. The firm adjusted targets in the drug distributor space…
Big tech is wobbling. Goldman Sachs says it's time to buy these 23 unloved stocks instead.
Goldman Sachs says consumer-facing laggard stocks are the best way forward as earnings growth is set to slow next year and big tech stocks struggle.
McKesson price target raised to $1,200 from $1,080 at UBS
UBS raised the firm’s price target on McKesson (MCK) to $1,200 from $1,080 and keeps a Buy rating on the shares.
CD&R, McKesson to Acquire At-Home Infusion Therapy Provider for $5.8 Billion
Under the agreement, CD&R will hold a majority interest of about 51% in Option Care Health, while McKesson will hold about 49%.
McKesson, CD&R to take infusion therapy provider Option Care private in $5.8 billion deal
Drug distributor McKesson and private equity firm Clayton Dubilier & Rice on Tuesday agreed to take infusion therapy provider Option Care Health private in a deal worth about $5.8 billion including ...
CD&R and McKesson Corporation Sign Agreement to Acquire Option Care Health
NEW YORK & IRVING, Texas & BANNOCKBURN, Ill.--(BUSINESS WIRE)--CD&R, McKesson Corporation (NYSE: MCK) (“McKesson”), and Option Care Health, Inc. (Nasdaq: OPCH) (“Option Care Health”) announced today t...
McKesson, CD&R near $5 billion-plus deal to buy Option Care, FT reports
Drug distributor McKesson and private equity firm Clayton Dubilier & Rice are nearing a deal to acquire infusion services provider Option Care Health in a transaction valued at more than $5 billion ...